Table 3.
Associations between mammographic density assessed with Breast Imaging-Reporting and Data System (BI-RADS) at diagnosis and recurrence-free survival following neoadjuvant chemotherapy.
| BI-RADS | Model 1 | Model 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| N | Events | HR (95% CI) | P value | N | Events | HR (95% CI) | P value | |
| a+b+c | 272 | 74 | ref | 254 | 66 | ref | ||
| d | 26 | 11 | 1.84 (0.98–3.48) | 0.059 | 25 | 10 | 1.96 (0.98–3.92) | 0.057 |
Model 1: crude analysis.
Model 2: adjusted for age (years, continuous), ER (pos/neg), HER2 (pos/neg), axillary node status (N0/N+), tumor size at diagnosis (mm, continuous), and pCR (yes/no).
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor 2; mm, millimeter; N0, no axillary node engagement; N+, axillary node engagement; pCR, complete pathological response.